Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Reviews |7 June 2011

Stereotactic Body Radiation Therapy: Scope of the Literature Free

Kelley Tipton, MPH; Jason H. Launders, MSc; Rohit Inamdar, MSc, DABR; Curtis Miyamoto, MD; Karen Schoelles, MD, SM

Kelley Tipton, MPH

Jason H. Launders, MSc

Rohit Inamdar, MSc, DABR

Curtis Miyamoto, MD

Karen Schoelles, MD, SM

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Disclaimer: The authors of this report are responsible for its content. Statements in the report should not be construed as endorsements by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Acknowledgment: The authors thank Eileen Erinoff, MSLIS, and Helen Dunn for providing literature retrieval and documentation management support and Lydia Dharia and Katherine Donahue for their assistance with the preparation of the technical brief.
Financial Support: This project was supported by the ECRI Institute Evidence-based Practice Center with funding from the Agency for Healthcare Research and Quality under contract 290-02-0019, U.S. Department of Health and Human Services.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2598.
Requests for Single Reprints: Karen Schoelles, MD, SM, Evidence-based Practice Center, ECRI Institute, 5200 Butler Pike, Plymouth Meeting, PA 19462-1298; email, kschoelles@ecri.org.
Current Author Addresses: Ms. Tipton and Dr. Schoelles: Evidence-based Practice Center, ECRI Institute, 5200 Butler Pike, Plymouth Meeting, PA 19462-1298.
Mr. Launders and Mr. Inamdar: ECRI Institute, 5200 Butler Pike, Plymouth Meeting, PA 19462-1298.
Dr. Miyamoto: Department of Radiation Oncology, Temple University School of Medicine, Temple University Hospital, 3401 North Broad Street, Philadelphia, PA 19140.
Author Contributions: Conception and design: K. Tipton, K. Schoelles.
Analysis and interpretation of the data: K. Tipton, J.H. Launders, C. Miyamoto, K. Schoelles.
Drafting of the article: K. Tipton, C. Miyamoto, K. Schoelles.
Critical revision of the article for important intellectual content: K. Tipton, J.H. Launders, R. Inamdar, C. Miyamoto, K. Schoelles.
Final approval of the article: C. Miyamoto, K. Schoelles.
Obtaining of funding: K. Schoelles.
Administrative, technical, or logistic support: J.H. Launders, K. Schoelles.
Collection and assembly of data: K. Tipton.
  • From the ECRI Institute Evidence-based Practice Center, Plymouth Meeting, and Temple University Hospital, Philadelphia, Pennsylvania.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Methods
    • Results
    • Discussion
    • Glossary
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

Abstract

Stereotactic body radiation therapy (SBRT) is derived from the techniques of stereotactic radiosurgery used to treat lesions in the brain and spine. It combines multiple finely collimated radiation beams and stereotaxy to deliver a high dose of radiation to an extracranial target in the body in a single dose or a few fractions.

This review provides a broad overview of the current state of SBRT for solid malignant tumors. Reviewers identified a total of 124 relevant studies. To our knowledge, no published comparative studies address the relative effectiveness and safety of SBRT versus other forms of external-beam radiation therapy. Stereotactic body radiation therapy seems to be widely diffused as a treatment of various types of cancer, although most studies have focused only on its use for treating thoracic tumors.

Comparative studies are needed to provide evidence that the theoretical advantages of SBRT over other radiation therapies actually occur in the clinical setting; this area is currently being studied in only 1 small trial.

Key Summary Points

  • Advances in planning and delivering radiation treatment have led to greater interest and capabilities to treat smaller and hard-to-target tumors while reducing treatment time.

  • Stereotactic body radiation therapy (SBRT) is typically delivered in 1 to 5 fractions, with a typical total dose of 20 to 60 Gy.

  • Stereotactic body radiation therapy seems to be widely used for treating various types of cancer, although most studies have focused only on its use to treat thoracic tumors. Fewer than 10 studies each for tumors of the pancreas, liver, colon, uterus, pelvis, sacrum, kidney, and prostate were found in this technical brief.

  • The American Association of Physicists in Medicine Task Group on SBRT has emphasized the importance of having well-trained and dedicated staff for providing SBRT in a safe environment.

  • No published comparative studies address the relative effectiveness and safety of SBRT versus other forms of external-beam radiation therapy. Only 1 small, ongoing trial is making such a comparison.

  • Comparative studies are needed to provide evidence that the theoretical advantages of SBRT over other radiotherapies actually occur in the clinical setting.

  • Future studies may help to determine the optimal number of radiation fractions, minimum and maximum doses per fraction, maximum number and diameter of lesions for various locations, and radiobiological explanations for the efficacy of SBRT.

Radiation has been used for the treatment of cancer since 1896, shortly after Roentgen's discovery of x-rays. External-beam radiation therapy is the most common method of radiation delivery; brachytherapy (placement of radioactive materials in or adjacent to the tumor) is another common method. Before external-beam radiation therapy, the target lesion is defined on imaging studies; a simulation is constructed; and a treatment plan is generated by radiation oncologists, dosimetrists, and radiation physicists. The use of 3-dimensional imaging techniques, such as computed tomography, positron emission tomography, or magnetic resonance imaging, for treatment simulation and planning has improved the accuracy of external-beam radiation therapy.
The software used in planning treatment incorporates data from the 3-dimensional images to more precisely define the target, normal tissues, and the isocenter at which the radiation will be delivered most intensely. Images taken at different times can be incorporated into the planning algorithms to account for movement of the target and surrounding structures during treatment, such as with respiration—this is called 4-dimensional conformal radiation therapy(1).
Another advance in the delivery of radiation is improved shaping of the radiation beam delivered to the tumor by using multileaf collimator systems located in the linear accelerator (linac). The multileaf collimator consists of multiple metal “leaves” that can be adjusted individually to shape the radiation beam to the contour of the tumor. Methods for reducing movement of the patient on the treatment table and of the tumor during treatment have also improved the accuracy of radiation delivery. For treatment of areas in the body, immobilization is accomplished by using abdominal-compression devices, vacuum pillows, masks, and stereotactic frames that fit tightly around the patient and are fixed to the treatment table.
Some delivery devices can track the position of the tumor and surrounding structures during the treatment, using implanted fiducials (radio-opaque markers), skin markers, or bony structures as reference points. A more recent trend is the use of image-guided radiation therapy before (or during) a treatment session to assess changes in the movement or shape of the tumor and the accuracy of delivery in real time. Digital orthogonal radiography is commonly done at the time of treatment, and results are compared with computed tomography–generated digital radiographs.
The improved ability to shape the radiation beam and spare surrounding tissues has led to a greater interest in reducing the number of fractions over which treatment is delivered. Treatment with 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy is typically divided into 25 to 50 fractions (approximately 2 Gy per fraction) delivered 5 days per week for approximately 5 to 10 weeks. Stereotactic radiosurgery, in contrast, delivers a high dose of radiation to cranial tumors in a single session. Stereotactic body radiation therapy is typically delivered in 1 to 5 fractions, with a typical total dose of 20 to 60 Gy. The Figure shows a device with SBRT capabilities.
Figure.
A linear accelerator–based stereotactic radiosurgery and stereotactic body radiation therapy system.

The system incorporates a high-definition, 120-leaf multileaf collimator; robotic couch; cone-beam computed tomography; and stereoradiograph target–verification system. (Photo courtesy of Varian Medical Systems, Palo Alto, California. All rights reserved.)

As of September 2009, we had identified 384 facilities listed in the AHA Guide to the Health Care Field 2009 Edition(2) that specifically stated their capacity to provide SBRT. Lanni and colleagues (3) compared the hospital charges for technical and professional treatment with SBRT with those of intensity-modulated radiation therapy and standard fractionated radiation therapy for medically inoperable non–small cell lung cancer (NSCLC) on the basis of the average number of delivered fractions (3). The average charge was $55 705 for 35 fractions of 3-dimensional conformal radiation therapy, $146 570 for 35 fractions of intensity-modulated radiation therapy, and $52 471 for 4 fractions of SBRT (3). The expected Medicare reimbursements (based on the 2010 Ambulatory Payment Classification) for the respective therapies were $13 639, $22 747, and $10 616 (3).
The Agency for Healthcare Research and Quality Effective Health Care Program requested a technical brief on SBRT. A technical brief is not intended to assess comparative effectiveness, but to provide an overview of key issues related to an emerging diagnostic or therapeutic technology. The goal of this technical brief is to provide a broad overview of the current state of SBRT for solid malignant tumors. Although some authors and organizations include treatment of lesions in the spine as a form of SBRT, others consider this stereotactic radiosurgery. Several terms have been used to describe SBRT in the published literature, such as stereotactic radiotherapy, fractionated stereotactic radiosurgery, hypofractionated stereotactic radiosurgery, and staged radiosurgery. For the purposes of this review, we will use the term SBRT and will not discuss treatment of spinal lesions. Other terms used in this article are defined in the 343.

Methods

Protocol

The protocol for the technical brief was developed in conjunction with the Agency for Healthcare Research and Quality. The protocol for the literature scan was developed by the ECRI Institute Evidence-based Practice Center, Plymouth Meeting, Pennsylvania, with input from ECRI Institute's medical physicists. Peer and public review of an early draft of the technical brief led to changes in terminology and scope based on recent consensus definitions. Proton, electron, and carbon ion therapy are outside the scope of this technical brief.

Search Strategy

We searched for published English-language studies by using the Ovid platform in MEDLINE; EMBASE; and Cochrane databases, including the Health Technology Assessment Database, from January 2000 to December 2010. Search terms included (but were not limited to) hypofractionated, stereotaxis, stereotactic, and single-fraction and text and Medical Subject Heading terms for cancer and devices. The full search strategy can be found in Appendix Tables 1 and 2.

Appendix Table 1.

Electronic Database Searches

Appendix Table 1.

Appendix Table 2.

Search Strings

Appendix Table 2.
We used Google to search for gray literature applicable to the background information, descriptions of instrumentation and accessories, and utilization. We separately searched Windhover Online, Healthcare News, The Gray Sheet, The Wall Street Journal, and Clinica. We visited the Web sites of related professional association and organizations (for example, the International RadioSurgery Association). We found information on instrumentation by searching manufacturers' Web sites and the U.S. Food and Drug Administration's Center for Devices and Radiological Health Web site (www.fda.gov/cdrh). Instrumentation information can be found in Supplement 1. We obtained additional information on device specifications and compatible accessories through interviews with manufacturers (available in the full report [4]).

Study Selection

Two reviewers screened abstracts and full-text articles, and a third reviewer assisted with disagreements. Eligible studies were clinical studies of any design; were published in English; had at least 3 patients with solid malignant tumors in the body (excluding head and spine) who received SBRT in 10 or fewer fractions; and reported any clinical outcomes, adverse events, or both. Studies not eligible for data extraction included those on treatment planning (for example, dosing) and treatment delivery (for example, accuracy) that did not report patient outcomes. A detailed list of the excluded articles and primary reason for exclusion can be found in the full report (4).

Data Extraction

We created standardized data extraction forms, and 2 reviewers entered data into the SRS 4.0 database (Mobius Analytics, Ottawa, Ontario, Canada). The information extracted (if reported) included cancer type, inclusion or exclusion criteria, patient outcomes, adverse events or harms, study design characteristics, treatment characteristics, patient characteristics, instrumentation, algorithms, and quality assurance or training procedures.

Data Analysis and Synthesis

We performed descriptive statistics for patient characteristics and length of follow-up. We described study types, patient populations, prior or concurrent treatment, devices and algorithms used, outcomes assessed, patient selection criteria reported by the studies, and adverse events.

Role of the Funding Source

The ECRI Institute Evidence-based Practice Center prepared this report, with funding from the Agency for Healthcare Research and Quality. Staff from the Agency for Healthcare Research and Quality participated in the formulation of the research questions and reviewed the methods and the draft report but were not involved in study selection, data extraction, or drafting of the manuscript for publication.

Results

Of the 5585 citations screened, 124 relevant studies were identified. These studies are summarized by cancer type in Appendix Table 3, and the study selection process is shown in the Appendix Figure.

Appendix Table 3.

Summary of SBRT Studies, by Cancer Type

Appendix Table 3.
Appendix Figure.
Summary of evidence search and selection.

Tumor Sites Where SBRT Has Been Used

The tumor sites most commonly represented in the included studies were the lung or thorax (n = 68). We found 27 studies of tumors in the pancreas, liver, and colon and fewer than 10 studies each of tumors in the uterus, pelvis, kidney, thyroid, and prostate. Ten studies included patients with various treatment sites.

Radiation, Instrumentation, and Algorithms Used

Photon radiation was used in all of the included studies. The instrumentations most frequently reported included modified linacs, CyberKnife (Accuray, Sunnyvale, California), Novalis Shaped Beam or Clinac (Varian Medical Systems, Palo Alto, California), TomoTherapy Hi-ART (TomoTherapy, Madison, Wisconsin), a fusion of computed tomography and linac, and the Synergy system (Elekta, Stockholm, Sweden).
Most studies described the treatment-planning techniques and treatment-delivery processes. Studies reported the use of 1 to 12 coplanar or noncoplanar radiation beams for treatment. Various body-immobilization techniques were used, including the Alpha Cradle (Smithers Medical, North Canton, Ohio) and the Stereotactic Body Frame (Elekta).
Computed tomography, magnetic resonance imaging, and positron emission tomography were often used to plan treatment. Treatment planning was conducted on software systems that typically were specific to the device used during treatment. Breath-holding, respiratory gating, and abdominal-compression techniques were used to control for respiratory movement. Finally, the type of image guidance (megavoltage or kilovoltage) used during treatment (that is, just before treatment began) included computed tomography, cone-beam computed tomography, and orthogonal radiography.
Doses and fractions of SBRT varied on the basis of such factors as the type of cancer and location of the tumor. Most published studies described delivery in 1 to 5 fractions; however, 14 studies delivered treatment in more than 5 fractions but still referred to this as SBRT (5–18).

Study Design, Study Size, and Follow-up

We identified 67 prospective single-group studies (Supplement 2) and 57 retrospective single-group studies (Supplement 3) of SBRT that met our inclusion criteria. The 2 categories of tumor sites with the most studies and patients were the lung or thorax, with 68 studies and 4418 patients, and gastrointestinal sites (colon, liver, or pancreas), with 27 studies and 1281 patients (Appendix Table 3). The shortest mean and median follow-ups were in the studies of multiple cancer sites (8.2 and 12.9 months, respectively; range, 1 to 95 months). Studies of tumors involving the pelvis, sacrum, and uterus had the longest mean and median follow-ups (31 and 33 months, respectively; range, 2 to 77 months).

Comparator Used in Comparative Studies

None of the included studies compared SBRT with another form of radiation treatment. We searched ClinicalTrials.gov and identified 50 ongoing SBRT trials. The trials include metastatic breast cancer and primary cancer of the biliary tract, kidney, liver, lung (principally NSCLC), pancreas, prostate, and unspecified sites. Only 1 of these ongoing trials involves a direct comparison of SBRT with a different form of radiation therapy. This trial (ClinicalTrials.gov identifier: NCT00870116) is a nonrandomized comparison of SBRT delivered by CyberKnife (enrollment target of 20 patients) versus SBRT delivered by linac (enrollment target of 80 patients) versus conformal radiation therapy without respiratory tracking (enrollment target of 20 patients) for NSCLC. The primary outcome measure is local control. The trial commenced in April 2009 in France and is still recruiting patients. Three other comparative trials are designed with historical controls, including 1 each for metastatic breast cancer (ClinicalTrials.gov identifier: NCT00167414), NSCLC (ClinicalTrials.gov identifier: NCT00727350), and pancreatic cancer (ClinicalTrials.gov identifier: NCT00350142). A randomized lung cancer trial based in the Netherlands (Clinical Trials.gov identifier: NCT00687986) is comparing SBRT with primary resection of the tumor. The primary outcomes are local control, regional control, quality of life, and treatment costs. The enrollment target was 960 patients, and completion was expected in December 2013; however, the trial was terminated in April 2011 because of poor recruitment. A trial conducted in China (Clinical Trials.gov identifier: NCT00840749) will compare SBRT with surgical resection in NSCLC. The enrollment target is 1030 patients, with planned completion also in 2013. Another trial (ClinicalTrials.gov identifier: NCT00843726), conducted at Roswell Park Cancer Institute, Buffalo, New York, will randomly assign 98 patients to either 1 or 3 fractions of SBRT for NSCLC. Appendix Table 4 includes further information on these 6 or 7 comparative trials. Additional ongoing trials of SBRT are described in the full report (4).

Appendix Table 4.

Comparative Clinical Trials Involving SBRT

Appendix Table 4.

Patient Selection Criteria

The most common selection criteria were inoperable tumors or patients declining surgery. Most studies required biopsy-proven disease before treatment and a minimum level of performance on the Karnofsky Performance Scale or the World Health Organization/Eastern Cooperative Oncology Group Performance Status scale, typically excluding patients with severe illness or disability. Patients who had received prior radiation therapy were typically excluded unless a minimum interval had elapsed before SBRT. Fifty-eight studies reported prior or concurrent treatment (for example, surgery, chemotherapy, and radiofrequency ablation).

Outcomes Measured

The outcomes most frequently assessed were tumor response (n = 55) (5, 8, 12, 14, 16, 19–68), local control (n = 55) (5–8, 10–12, 14, 16–18, 33–35, 55–57, 59–61, 63, 68–101), overall survival (n = 48) (5, 7, 8, 10–12, 17, 24, 27, 31, 34, 44, 45, 57, 59–64, 66, 68, 69, 71–75, 77, 81–84, 86, 88, 90, 92, 93, 95, 97–105), and toxicity (n = 42) (5, 7, 13, 34, 39, 42, 44, 45, 48, 51, 60–66, 68, 69, 72, 73, 75, 81, 83, 94–99, 104–115).

Adverse Events Reported

Many of the studies used the Radiation Therapy Oncology Group criteria and Common Toxicity Criteria, Version 2.0, to grade acute and late toxicity. A total of 113 studies reported acute or late adverse events. The most frequently reported adverse events were pain, fatigue, nausea, bleeding, and diarrhea. Study authors noted that some patients with these events had received prior treatment for cancer, received SBRT for recurring cancer, or had comorbid conditions. One study of SBRT for renal cell cancer reported no adverse effects of treatment (54).

Discussion

Stereotactic body radiation therapy is a treatment option that is likely to be attractive to patients because of the convenience of fewer treatment sessions. The radiation oncologist may decide whether to use SBRT in any given patient on the basis of the patient's radiation history (in particular, prior radiation of the site to be treated), proposed treatment volume, function of the involved or nearby organs, the patient's capacity for recovery, patient preference, the number of tumor sites, and many other cancer-related factors (116).
Although many published studies describe SBRT, several limitations in the available literature raise concerns about the widespread use of SBRT. To date, no published comparative studies (either randomized or nonrandomized prospective studies) have addressed the relative effectiveness and safety of SBRT versus other forms of external-beam radiation therapy. Also, SBRT seems to be widely disseminated for treatment of various cancer types, although most of the studies (n = 68) were for SBRT for tumors located in the lung or thorax. We found fewer than 10 studies each of tumors of the pancreas, liver, colon, uterus, pelvis, sacrum, kidney, and prostate. A Medicare Evidence Development and Coverage Advisory Committee proceeding from April 2010 considered the evidence for radiation therapy for localized prostate cancer (117). The panel of 15 experts was asked to state its level of confidence in the evidence for improvement of mortality (survival and death rates), functional outcomes (erectile dysfunction, urinary incontinence, and fecal incontinence), and adverse events (rectal fistula, radiation burns, and infection) with SBRT compared with classical fractionated external-beam radiation therapy for localized prostate cancer. On a scale of 1 (low confidence) to 5 (high confidence), the average score was 1.07 for mortality, 1.13 for functional outcomes, and 1.33 for adverse events (117).
To date, 7 systematic reviews assessing SBRT for cancer have been published. Three assessed its use in NSCLC (118–120), 2 in multiple sites (for example, liver and pancreas) (121, 122), 1 in liver cancer (123), and 1 in pulmonary metastasis (124). The general consensus among these reviews is that although single-group studies show potentially promising results for various cancer sites, prospective studies are necessary to determine the efficacy of SBRT compared with other available treatment options (for example, surgery or radiation therapy). Appendix Table 5 provides more detail regarding these reviews.

Appendix Table 5.

Systematic Reviews

Appendix Table 5.
Such groups as the American Association of Physicists in Medicine have also urged participation in trials sponsored by the National Cancer Institute or in trials run by the National Cancer Institute–sponsored Radiation Therapy Oncology Group, a multi-institutional research cooperative. In a recent guidance document, the American Association of Physicists in Medicine pointed out that protocol-driven treatment in the context of such studies would reflect the guidelines produced by experts in the field (125). Future studies may help to determine the optimal number of radiation fractions, minimum and maximum doses per fraction, maximum number and diameter of lesions for various locations, and radiobiological explanations for the efficacy of SBRT.
Chang and Timmerman (126) point out that more multicenter trials are needed to corroborate results in single-institution trials and, like others (116), noted that longer-term follow-up will be necessary to assess late toxicities from SBRT. In addition, they point out that although the relative effectiveness and safety of the various devices available for delivering SBRT need further study, the training and experience of the operators may be of greater importance (126). The American Association of Physicists in Medicine Task Group on SBRT has emphasized the importance of having well-trained and dedicated staff for providing SBRT and points out the procedures that need to be performed by such personnel to ensure patient safety (125).
In summary, there are many publications on SBRT for cancer, principally NSCLC. Comparative studies (preferably randomized trials, but at least trials with concurrent controls) are needed to provide convincing evidence that the theoretical advantages of SBRT over other radiation therapies actually occur in the clinical setting. Appropriate comparators for SBRT studies may depend on the treatment site, tumor size, or feasibility of other forms of radiation therapy (for example, intensity-modulated radiation therapy or proton-beam therapy) or surgery for the patient population. At present, only 1 small, ongoing trial is making such a comparison. Consequently, a full systematic review of the current literature cannot answer questions on the effectiveness and safety of SBRT compared with other radiotherapy interventions. One large ongoing trial scheduled for completion in 2013 has the potential to answer questions about the effectiveness and safety of SBRT compared with surgical resection in patients with resectable early-stage lung cancer.

Glossary

Brachytherapy: The placement of temporary or permanent radioactive material inside the body.
Cone-beam computed tomography: Often built into linear accelerators and uses a cone-shaped radiation field to obtain images over 1 to several minutes. The image is then modified to allow viewing in a usual coronal, transaxial, and sagittal format to allow high-precision targeting.
Computed tomography: Produces images based on a cross-sectional view of the body obtained from different projections in a given plane.
Coplanar: Within the same plane.
External-beam radiation therapy: Radiation therapy delivered from outside the body.
Fiducials: Markers that help to precisely identify the targeted tumor location. They may be located on a surface or surgically implanted for tumor locations throughout the body.
Four-dimensional conformal radiation therapy: Measures the natural tumor motion that occurs during treatment, such as from breathing. The measurements are included in the treatment plan to ensure that the tumor is targeted throughout the treatment course.
Fraction: A prescribed total treatment dose divided into smaller amounts.
Image-guided radiation therapy: The use of imaging methods (such as computed tomography) to assist in targeting a lesion during radiation treatment.
Intensity-modulated radiation therapy: Therapy that delivers radiation beams with varying intensities.
Isocenter: The center of the treatment area in relation to the paths of the radiation beams.
Linear accelerator (linac): Radiography machine that emits photon- or electron-radiation megavolts redirected in many arcs for treating benign or malignant lesions throughout the body.
Magnetic resonance imaging: Produces images by using high-field magnets and radiofrequency energies that can be acquired along any direction without using ionizing radiation. It is particularly useful for soft-tissue discrimination.
Multileaf collimator: Located in the linear particle accelerator and consists of multiple metal “leaves” that can be adjusted individually to shape the radiation beam to the contour of the tumor and to variably modulate the dose.
Noncoplanar: Within different planes.
Positron emission tomography: Produces images to evaluate biological function by detecting gamma radiation emitted from a positron-emitting compound that is injected into the patient (fluorodeoxyglucose is common).
Respiratory gating: Tracking patient's normal respiratory cycle with an infrared camera and a marker placed on the chest or abdomen or other methods.
Stereotaxy: Three-dimensional target localization. Stereotactic frames provide reference points (coordinates) in 3 dimensions.
Three-dimensional conformal radiation therapy: A 3-dimensional planning system to deliver radiation to the tumor.

References

  1. Bucci
    MK
    ,  
    Bevan
    A
    ,  
    Roach
    M
    3rd
    .  
    Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond.
    CA Cancer J Clin
    2005
    55
    117
    34
     PubMed
    CrossRef
  2. American Hospital Association
    AHA Guide to the Health Care Field 2009 Edition.
    Chicago
    American Hosp Assoc
    2008
  3. Lanni
    TB
    Jr
    ,  
    Grills
    IS
    ,  
    Kestin
    LL
    ,  
    Robertson
    JM
    .  
    Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Am J Clin Oncol
    2010
     PubMed
  4. Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, et al. Stereotactic Body Radiation Therapy. Technical Brief no. 6. (Prepared by ECRI Institute Evidence-based Practice Center under Contract no. HHSA-290-02-0019.) AHRQ Publication no. 10 (11)-EHC058-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2011. Available atwww.effectivehealthcare.ahrq.gov/reports/final.cfm.
  5. Chawla
    S
    ,  
    Chen
    Y
    ,  
    Katz
    AW
    ,  
    Muhs
    AG
    ,  
    Philip
    A
    ,  
    Okunieff
    P
    .  et al. 
    Stereotactic body radiotherapy for treatment of adrenal metastases.
    Int J Radiat Oncol Biol Phys
    2009
    75
    71
    5
     PubMed
  6. Guckenberger
    M
    ,  
    Wulf
    J
    ,  
    Mueller
    G
    ,  
    Krieger
    T
    ,  
    Baier
    K
    ,  
    Gabor
    M
    .  et al. 
    Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.
    Int J Radiat Oncol Biol Phys
    2009
    74
    47
    54
     PubMed
  7. Haasbeek
    CJ
    ,  
    Lagerwaard
    FJ
    ,  
    de Jaeger
    K
    ,  
    Slotman
    BJ
    ,  
    Senan
    S
    .  
    Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy.
    Cancer
    2009
    115
    587
    94
     PubMed
  8. Lee
    MT
    ,  
    Kim
    JJ
    ,  
    Dinniwell
    R
    ,  
    Brierley
    J
    ,  
    Lockwood
    G
    ,  
    Wong
    R
    .  et al. 
    Phase I study of individualized stereotactic body radiotherapy of liver metastases.
    J Clin Oncol
    2009
    27
    1585
    91
     PubMed
  9. Milano
    MT
    ,  
    Katz
    AW
    ,  
    Okunieff
    P
    .  
    Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ.
    Am J Clin Oncol
    2010
    33
    157
    63
     PubMed
  10. Stephans
    KL
    ,  
    Djemil
    T
    ,  
    Reddy
    CA
    ,  
    Gajdos
    SM
    ,  
    Kolar
    M
    ,  
    Machuzak
    M
    .  et al. 
    Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.
    J Thorac Oncol
    2009
    4
    838
    44
     PubMed
  11. Lagerwaard
    FJ
    ,  
    Haasbeek
    CJ
    ,  
    Smit
    EF
    ,  
    Slotman
    BJ
    ,  
    Senan
    S
    .  
    Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys
    2008
    70
    685
    92
     PubMed
  12. Aoki
    M
    ,  
    Abe
    Y
    ,  
    Kondo
    H
    ,  
    Hatayama
    Y
    ,  
    Kawaguchi
    H
    ,  
    Fujimori
    A
    .  et al. 
    Clinical outcome of stereotactic body radiotherapy of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system.
    Radiat Med
    2007
    25
    289
    94
     PubMed
  13. Dawson
    LA
    ,  
    Eccles
    C
    ,  
    Craig
    T
    .  
    Individualized image guided iso-NTCP based liver cancer SBRT.
    Acta Oncol
    2006
    45
    856
    64
     PubMed
  14. Guckenberger
    M
    ,  
    Heilman
    K
    ,  
    Wulf
    J
    ,  
    Mueller
    G
    ,  
    Beckmann
    G
    ,  
    Flentje
    M
    .  
    Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study.
    Radiother Oncol
    2007
    85
    435
    42
     PubMed
  15. Katoh
    N
    ,  
    Onimaru
    R
    ,  
    Sakuhara
    Y
    ,  
    Abo
    D
    ,  
    Shimizu
    S
    ,  
    Taguchi
    H
    .  et al. 
    Real-time tumor-tracking radiotherapy for adrenal tumors.
    Radiother Oncol
    2008
    87
    418
    24
     PubMed
  16. Tse
    RV
    ,  
    Hawkins
    M
    ,  
    Lockwood
    G
    ,  
    Kim
    JJ
    ,  
    Cummings
    B
    ,  
    Knox
    J
    .  et al. 
    Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Clin Oncol
    2008
    26
    657
    64
     PubMed
  17. Uematsu
    M
    ,  
    Shioda
    A
    ,  
    Suda
    A
    ,  
    Fukui
    T
    ,  
    Ozeki
    Y
    ,  
    Hama
    Y
    .  et al. 
    Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience.
    Int J Radiat Oncol Biol Phys
    2001
    51
    666
    70
     PubMed
  18. Xia
    T
    ,  
    Li
    H
    ,  
    Sun
    Q
    ,  
    Wang
    Y
    ,  
    Fan
    N
    ,  
    Yu
    Y
    .  et al. 
    Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys
    2006
    66
    117
    25
     PubMed
  19. Gunvén
    P
    ,  
    Blomgren
    H
    ,  
    Lax
    I
    .  
    Radiosurgery for recurring liver metastases after hepatectomy.
    Hepatogastroenterology
    2003
    50
    1201
    4
     PubMed
  20. Sinha
    B
    ,  
    McGarry
    RC
    .  
    Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience.
    Int J Radiat Oncol Biol Phys
    2006
    66
    1120
    4
     PubMed
  21. Baumann
    P
    ,  
    Nyman
    J
    ,  
    Lax
    I
    ,  
    Friesland
    S
    ,  
    Hoyer
    M
    ,  
    RehnEricsson
    S
    .  et al. 
    Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
    Acta Oncol
    2006
    45
    787
    95
     PubMed
  22. Teh
    BS
    ,  
    Paulino
    AC
    ,  
    Lu
    HH
    ,  
    Chiu
    JK
    ,  
    Richardson
    S
    ,  
    Chiang
    S
    .  et al. 
    Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites.
    Technol Cancer Res Treat
    2007
    6
    347
    54
     PubMed
  23. Brown
    WT
    ,  
    Wu
    X
    ,  
    Wen
    BC
    ,  
    Fowler
    JF
    ,  
    Fayad
    F
    ,  
    Amendola
    BE
    .  et al. 
    Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors.
    Comput Aided Surg
    2007
    12
    253
    61
     PubMed
  24. Norihisa
    Y
    ,  
    Nagata
    Y
    ,  
    Takayama
    K
    ,  
    Matsuo
    Y
    ,  
    Sakamoto
    T
    ,  
    Sakamoto
    M
    .  et al. 
    Stereotactic body radiotherapy for oligometastatic lung tumors.
    Int J Radiat Oncol Biol Phys
    2008
    72
    398
    403
     PubMed
  25. Kunos
    C
    ,  
    von Gruenigen
    V
    ,  
    Waggoner
    S
    ,  
    Brindle
    J
    ,  
    Zhang
    Y
    ,  
    Myers
    B
    .  et al. 
    Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy.
    Technol Cancer Res Treat
    2008
    7
    375
    80
     PubMed
  26. Kim
    MS
    ,  
    Choi
    C
    ,  
    Yoo
    S
    ,  
    Cho
    C
    ,  
    Seo
    Y
    ,  
    Ji
    Y
    .  et al. 
    Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma.
    Jpn J Clin Oncol
    2008
    38
    695
    700
     PubMed
  27. Jereczek-Fossa
    BA
    ,  
    Kowalczyk
    A
    ,  
    D'Onofrio
    A
    ,  
    Catalano
    G
    ,  
    Garibaldi
    C
    ,  
    Boboc
    G
    .  et al. 
    Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients.
    Strahlenther Onkol
    2008
    184
    36
    40
     PubMed
  28. Fritz
    P
    ,  
    Kraus
    HJ
    ,  
    Blaschke
    T
    ,  
    Mühlnickel
    W
    ,  
    Strauch
    K
    ,  
    Engel-Riedel
    W
    .  et al. 
    Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning.
    Lung Cancer
    2008
    60
    193
    9
     PubMed
  29. Coon
    D
    ,  
    Gokhale
    AS
    ,  
    Burton
    SA
    ,  
    Heron
    DE
    ,  
    Ozhasoglu
    C
    ,  
    Christie
    N
    .  
    Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Clin Lung Cancer
    2008
    9
    217
    21
     PubMed
  30. Choi
    BO
    ,  
    Choi
    IB
    ,  
    Jang
    HS
    ,  
    Kang
    YN
    ,  
    Jang
    JS
    ,  
    Bae
    SH
    .  et al. 
    Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
    BMC Cancer
    2008
    8
    351
     PubMed
  31. Casamassima
    F
    ,  
    Masi
    L
    ,  
    Bonucci
    I
    ,  
    Polli
    C
    ,  
    Menichelli
    C
    ,  
    Gulisano
    M
    .  et al. 
    Relevance of biologically equivalent dose values in outcome evaluation of stereotactic radiotherapy for lung nodules.
    Int J Radiat Oncol Biol Phys
    2008
    71
    145
    51
     PubMed
  32. Pennathur
    A
    ,  
    Luketich
    JD
    ,  
    Heron
    DE
    ,  
    Abbas
    G
    ,  
    Burton
    S
    ,  
    Chen
    M
    .  et al. 
    Stereotactic radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients.
    J Thorac Cardiovasc Surg
    2009
    137
    597
    604
     PubMed
  33. McCammon
    R
    ,  
    Schefter
    TE
    ,  
    Gaspar
    LE
    ,  
    Zaemisch
    R
    ,  
    Gravdahl
    D
    ,  
    Kavanagh
    B
    .  
    Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy.
    Int J Radiat Oncol Biol Phys
    2009
    73
    112
    8
     PubMed
  34. Choi
    CW
    ,  
    Cho
    CK
    ,  
    Yoo
    SY
    ,  
    Kim
    MS
    ,  
    Yang
    KM
    ,  
    Yoo
    HJ
    .  et al. 
    Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer.
    Int J Radiat Oncol Biol Phys
    2009
    74
    147
    53
     PubMed
  35. Ahn
    SH
    ,  
    Han
    MS
    ,  
    Yoon
    JH
    ,  
    Jeon
    SY
    ,  
    Kim
    CH
    ,  
    Yoo
    HJ
    .  et al. 
    Treatment of stage I non-small cell lung cancer with CyberKnife, image-guided robotic stereotactic radiosurgery.
    Oncol Rep
    2009
    21
    693
    6
     PubMed
  36. Nakagawa
    K
    ,  
    Aoki
    Y
    ,  
    Tago
    M
    ,  
    Terahara
    A
    ,  
    Ohtomo
    K
    .  
    Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: original research in the treatment of thoracic neoplasms.
    Int J Radiat Oncol Biol Phys
    2000
    48
    449
    57
     PubMed
  37. Harada
    T
    ,  
    Shirato
    H
    ,  
    Ogura
    S
    ,  
    Oizumi
    S
    ,  
    Yamazaki
    K
    ,  
    Shimizu
    S
    .  et al. 
    Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy.
    Cancer
    2002
    95
    1720
    7
     PubMed
  38. Whyte
    RI
    ,  
    Crownover
    R
    ,  
    Murphy
    MJ
    ,  
    Martin
    DP
    ,  
    Rice
    TW
    ,  
    DeCamp
    MM
    Jr
    .  et al. 
    Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial.
    Ann Thorac Surg
    2003
    75
    1097
    101
     PubMed
  39. Lee
    SW
    ,  
    Choi
    EK
    ,  
    Park
    HJ
    ,  
    Ahn
    SD
    ,  
    Kim
    JH
    ,  
    Kim
    KJ
    .  et al. 
    Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung.
    Lung Cancer
    2003
    40
    309
    15
     PubMed
  40. Onishi
    H
    ,  
    Kuriyama
    K
    ,  
    Komiyama
    T
    ,  
    Tanaka
    S
    ,  
    Sano
    N
    ,  
    Marino
    K
    .  et al. 
    Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner.
    Lung Cancer
    2004
    45
    45
    55
     PubMed
  41. Ishimori
    T
    ,  
    Saga
    T
    ,  
    Nagata
    Y
    ,  
    Nakamoto
    Y
    ,  
    Higashi
    T
    ,  
    Mamede
    M
    .  et al. 
    18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.
    Ann Nucl Med
    2004
    18
    669
    74
     PubMed
  42. Song
    DY
    ,  
    Benedict
    SH
    ,  
    Cardinale
    RM
    ,  
    Chung
    TD
    ,  
    Chang
    MG
    ,  
    Schmidt-Ullrich
    RK
    .  
    Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits.
    Am J Clin Oncol
    2005
    28
    591
    6
     PubMed
  43. Shioyama
    Y
    ,  
    Nakamura
    K
    ,  
    Anai
    S
    ,  
    Sasaki
    T
    ,  
    Ooga
    S
    ,  
    Saku
    M
    .  et al. 
    Stereotactic radiotherapy for lung and liver tumors using a body cast system: setup accuracy and preliminary clinical outcome.
    Radiat Med
    2005
    23
    407
    13
     PubMed
  44. Hoyer
    M
    ,  
    Roed
    H
    ,  
    Sengelov
    L
    ,  
    Traberg
    A
    ,  
    Ohlhuis
    L
    ,  
    Pedersen
    J
    .  et al. 
    Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.
    Radiother Oncol
    2005
    76
    48
    53
     PubMed
  45. Zimmermann
    FB
    ,  
    Geinitz
    H
    ,  
    Schill
    S
    ,  
    Thamm
    R
    ,  
    Nieder
    C
    ,  
    Schratzenstaller
    U
    .  et al. 
    Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
    Acta Oncol
    2006
    45
    796
    801
     PubMed
  46. Yoon
    SM
    ,  
    Choi
    EK
    ,  
    Lee
    SW
    ,  
    Yi
    BY
    ,  
    Ahn
    SD
    ,  
    Shin
    SS
    .  et al. 
    Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors.
    Acta Oncol
    2006
    45
    1108
    14
     PubMed
  47. Timmerman
    R
    ,  
    McGarry
    R
    ,  
    Yiannoutsos
    C
    ,  
    Papiez
    L
    ,  
    Tudor
    K
    ,  
    DeLuca
    J
    .  et al. 
    Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
    J Clin Oncol
    2006
    24
    4833
    9
     PubMed
  48. Svedman
    C
    ,  
    Sandström
    P
    ,  
    Pisa
    P
    ,  
    Blomgren
    H
    ,  
    Lax
    I
    ,  
    Kälkner
    KM
    .  et al. 
    A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.
    Acta Oncol
    2006
    45
    870
    5
     PubMed
  49. Nuyttens
    JJ
    ,  
    Prévost
    JB
    ,  
    Praag
    J
    ,  
    Hoogeman
    M
    ,  
    Van Klaveren
    RJ
    ,  
    Levendag
    PC
    .  et al. 
    Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results.
    Acta Oncol
    2006
    45
    961
    5
     PubMed
  50. Le
    QT
    ,  
    Loo
    BW
    ,  
    Ho
    A
    ,  
    Cotrutz
    C
    ,  
    Koong
    AC
    ,  
    Wakelee
    H
    .  et al. 
    Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors.
    J Thorac Oncol
    2006
    1
    802
    9
     PubMed
  51. Hoyer
    M
    ,  
    Roed
    H
    ,  
    Traberg Hansen
    A
    ,  
    Ohlhuis
    L
    ,  
    Petersen
    J
    ,  
    Nellemann
    H
    .  et al. 
    Phase II study on stereotactic body radiotherapy of colorectal metastases.
    Acta Oncol
    2006
    45
    823
    30
     PubMed
  52. Hodge
    W
    ,  
    Tom
    WA
    ,  
    Jaradat
    HA
    ,  
    Orton
    NP
    ,  
    Khuntia
    D
    ,  
    Traynor
    A
    .  et al. 
    Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation.
    Acta Oncol
    2006
    45
    890
    6
     PubMed
  53. Ricardi
    U
    ,  
    Guarneri
    A
    ,  
    Mantovani
    C
    ,  
    Ciammella
    P
    ,  
    Giglioli
    FR
    ,  
    Ragona
    R
    .  
    Stereotactic body radiation therapy for early non-small cell lung cancer: experience at the University of Turin.
    J Thorac Oncol
    2007
    2
    S47
     PubMed
  54. Ponsky
    LE
    ,  
    Mahadevan
    A
    ,  
    Gill
    IS
    ,  
    Djemil
    T
    ,  
    Novick
    AC
    .  
    Renal radiosurgery: initial clinical experience with histological evaluation.
    Surg Innov
    2007
    14
    265
    9
     PubMed
  55. Salazar
    OM
    ,  
    Sandhu
    TS
    ,  
    Lattin
    PB
    ,  
    Chang
    JH
    ,  
    Lee
    CK
    ,  
    Groshko
    GA
    .  et al. 
    Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Int J Radiat Oncol Biol Phys
    2008
    72
    707
    15
     PubMed
  56. Chang
    JY
    ,  
    Balter
    PA
    ,  
    Dong
    L
    ,  
    Yang
    Q
    ,  
    Liao
    Z
    ,  
    Jeter
    M
    .  et al. 
    Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys
    2008
    72
    967
    71
     PubMed
  57. Kopek
    N
    ,  
    Paludan
    M
    ,  
    Petersen
    J
    ,  
    Hansen
    AT
    ,  
    Grau
    C
    ,  
    Høyer
    M
    .  
    Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.
    Radiother Oncol
    2009
    93
    402
    7
     PubMed
  58. Collins
    BT
    ,  
    Vahdat
    S
    ,  
    Erickson
    K
    ,  
    Collins
    SP
    ,  
    Suy
    S
    ,  
    Yu
    X
    .  et al. 
    Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer.
    J Hematol Oncol
    2009
    2
    1
     PubMed
  59. Timmerman
    R
    ,  
    Paulus
    R
    ,  
    Galvin
    J
    ,  
    Michalski
    J
    ,  
    Straube
    W
    ,  
    Bradley
    J
    .  et al. 
    Stereotactic body radiation therapy for inoperable early stage lung cancer.
    JAMA
    2010
    303
    1070
    6
     PubMed
  60. Polistina
    F
    ,  
    Costantin
    G
    ,  
    Casamassima
    F
    ,  
    Francescon
    P
    ,  
    Guglielmi
    R
    ,  
    Panizzoni
    G
    .  et al. 
    Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
    Ann Surg Oncol
    2010
    17
    2092
    101
     PubMed
  61. Dunlap
    NE
    ,  
    Cai
    J
    ,  
    Biedermann
    GB
    ,  
    Yang
    W
    ,  
    Benedict
    SH
    ,  
    Sheng
    K
    .  et al. 
    Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys
    2010
    76
    796
    801
     PubMed
  62. Crabtree
    TD
    ,  
    Denlinger
    CE
    ,  
    Meyers
    BF
    ,  
    El
    Naqa
    I
    ,  
    Zoole
    J
    ,  
    Krupnick
    AS
    .  et al. 
    Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg
    2010
    140
    377
    86
     PubMed
  63. Louis
    C
    ,  
    Dewas
    S
    ,  
    Mirabel
    X
    ,  
    Lacornerie
    T
    ,  
    Adenis
    A
    ,  
    Bonodeau
    F
    .  et al. 
    Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results.
    Technol Cancer Res Treat
    2010
    9
    479
    87
     PubMed
  64. Cárdenes
    HR
    ,  
    Price
    TR
    ,  
    Perkins
    SM
    ,  
    Maluccio
    M
    ,  
    Kwo
    P
    ,  
    Breen
    TE
    .  et al. 
    Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
    Clin Transl Oncol
    2010
    12
    218
    25
     PubMed
  65. Shin
    YJ
    ,  
    Kim
    MS
    ,  
    Yoo
    SY
    ,  
    Cho
    CK
    ,  
    Seo
    YS
    ,  
    Kang
    JK
    .  et al. 
    Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies.
    Tumori
    2010
    96
    65
    70
     PubMed
  66. Yang
    ZX
    ,  
    Wang
    D
    ,  
    Wang
    G
    ,  
    Zhang
    QH
    ,  
    Liu
    JM
    ,  
    Peng
    P
    .  et al. 
    Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma.
    J Cancer Res Clin Oncol
    2010
    136
    625
    30
     PubMed
  67. Kim
    JH
    ,  
    Kim
    MS
    ,  
    Yoo
    SY
    ,  
    Lim
    SM
    ,  
    Lee
    GH
    ,  
    Yi
    KH
    .  
    Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer.
    Otolaryngol Head Neck Surg
    2010
    142
    338
    43
     PubMed
  68. Kang
    JK
    ,  
    Kim
    MS
    ,  
    Kim
    JH
    ,  
    Yoo
    SY
    ,  
    Cho
    CK
    ,  
    Yang
    KM
    .  et al. 
    Oligometastases confined one organ from colorectal cancer treated by SBRT.
    Clin Exp Metastasis
    2010
    27
    273
    8
     PubMed
  69. Kopek
    N
    ,  
    Holt
    MI
    ,  
    Hansen
    AT
    ,  
    Høyer
    M
    .  
    Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
    Radiother Oncol
    2010
    94
    47
    52
     PubMed
  70. Vahdat
    S
    ,  
    Oermann
    EK
    ,  
    Collins
    SP
    ,  
    Yu
    X
    ,  
    Abedalthagafi
    M
    ,  
    Debrito
    P
    .  et al. 
    CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    J Hematol Oncol
    2010
    3
    6
     PubMed
  71. Kim
    MS
    ,  
    Yoo
    SY
    ,  
    Cho
    CK
    ,  
    Yoo
    HJ
    ,  
    Choi
    CW
    ,  
    Seo
    YS
    .  et al. 
    Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer.
    Oncology
    2009
    76
    212
    9
     PubMed
  72. Rusthoven
    KE
    ,  
    Kavanagh
    BD
    ,  
    Cardenes
    H
    ,  
    Stieber
    VW
    ,  
    Burri
    SH
    ,  
    Feigenberg
    SJ
    .  et al. 
    Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
    J Clin Oncol
    2009
    27
    1572
    8
     PubMed
  73. Rusthoven
    KE
    ,  
    Kavanagh
    BD
    ,  
    Burri
    SH
    ,  
    Chen
    C
    ,  
    Cardenes
    H
    ,  
    Chidel
    MA
    .  et al. 
    Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.
    J Clin Oncol
    2009
    27
    1579
    84
     PubMed
  74. van der Voort van Zyp
    NC
    ,  
    Prévost
    JB
    ,  
    Hoogeman
    MS
    ,  
    Praag
    J
    ,  
    van der Holt
    B
    ,  
    Levendag
    PC
    .  et al. 
    Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome.
    Radiother Oncol
    2009
    91
    296
    300
     PubMed
  75. Schellenberg
    D
    ,  
    Goodman
    KA
    ,  
    Lee
    F
    ,  
    Chang
    S
    ,  
    Kuo
    T
    ,  
    Ford
    JM
    .  et al. 
    Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Int J Radiat Oncol Biol Phys
    2008
    72
    678
    86
     PubMed
  76. Hof
    H
    ,  
    Hoess
    A
    ,  
    Oetzel
    D
    ,  
    Debus
    J
    ,  
    Herfarth
    K
    .  
    Stereotactic single-dose radiotherapy of lung metastases.
    Strahlenther Onkol
    2007
    183
    673
    8
     PubMed
  77. Hof
    H
    ,  
    Muenter
    M
    ,  
    Oetzel
    D
    ,  
    Hoess
    A
    ,  
    Debus
    J
    ,  
    Herfarth
    K
    .  
    Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).
    Cancer
    2007
    110
    148
    55
     PubMed
  78. Nuyttens
    JJ
    ,  
    Prevost
    JB
    ,  
    Van der Voort van Zijp
    NC
    ,  
    Hoogeman
    M
    ,  
    Levendag
    PC
    .  
    Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity.
    Technol Cancer Res Treat
    2007
    6
    605
    10
     PubMed
  79. Ernst-Stecken
    A
    ,  
    Lambrecht
    U
    ,  
    Mueller
    R
    ,  
    Sauer
    R
    ,  
    Grabenbauer
    G
    .  
    Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study.
    Strahlenther Onkol
    2006
    182
    696
    702
     PubMed
  80. Méndez Romero
    A
    ,  
    Wunderink
    W
    ,  
    Hussain
    SM
    ,  
    DePooter
    JA
    ,  
    Heijmen
    BJ
    ,  
    Nowak
    PC
    .  et al. 
    Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study.
    Acta Oncol
    2006
    45
    831
    7
     PubMed
  81. Wulf
    J
    ,  
    Guckenberger
    M
    ,  
    Haedinger
    U
    ,  
    Oppitz
    U
    ,  
    Mueller
    G
    ,  
    Baier
    K
    .  et al. 
    Stereotactic radiotherapy of primary liver cancer and hepatic metastases.
    Acta Oncol
    2006
    45
    838
    47
     PubMed
  82. Wulf
    J
    ,  
    Hädinger
    U
    ,  
    Oppitz
    U
    ,  
    Thiele
    W
    ,  
    Ness-Dourdoumas
    R
    ,  
    Flentje
    M
    .  
    Stereotactic radiotherapy of targets in the lung and liver.
    Strahlenther Onkol
    2001
    177
    645
    55
     PubMed
  83. Mahadevan
    A
    ,  
    Jain
    S
    ,  
    Goldstein
    M
    ,  
    Miksad
    R
    ,  
    Pleskow
    D
    ,  
    Sawhney
    M
    .  et al. 
    Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Int J Radiat Oncol Biol Phys
    2010
    78
    735
    42
     PubMed
  84. Chang
    DT
    ,  
    Schellenberg
    D
    ,  
    Shen
    J
    ,  
    Kim
    J
    ,  
    Goodman
    KA
    ,  
    Fisher
    GA
    .  et al. 
    Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
    Cancer
    2009
    115
    665
    72
     PubMed
  85. Milano
    MT
    ,  
    Chen
    Y
    ,  
    Katz
    AW
    ,  
    Philip
    A
    ,  
    Schell
    MC
    ,  
    Okunieff
    P
    .  
    Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy.
    Radiother Oncol
    2009
    91
    301
    6
     PubMed
  86. Stephans
    KL
    ,  
    Djemil
    T
    ,  
    Reddy
    CA
    ,  
    Gajdos
    SM
    ,  
    Kolar
    M
    ,  
    Mason
    D
    .  et al. 
    A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience.
    J Thorac Oncol
    2009
    4
    976
    82
     PubMed
  87. Song
    SY
    ,  
    Choi
    W
    ,  
    Shin
    SS
    ,  
    Lee
    SW
    ,  
    Ahn
    SD
    ,  
    Kim
    JH
    .  et al. 
    Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
    Lung Cancer
    2009
    66
    89
    93
     PubMed
  88. Takeda
    A
    ,  
    Sanuki
    N
    ,  
    Kunieda
    E
    ,  
    Ohashi
    T
    ,  
    Oku
    Y
    ,  
    Takeda
    T
    .  et al. 
    Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Int J Radiat Oncol Biol Phys
    2009
    73
    442
    8
     PubMed
  89. Baumann
    P
    ,  
    Nyman
    J
    ,  
    Hoyer
    M
    ,  
    Gagliardi
    G
    ,  
    Lax
    I
    ,  
    Wennberg
    B
    .  et al. 
    Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer—a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.
    Radiother Oncol
    2008
    88
    359
    67
     PubMed
  90. Onimaru
    R
    ,  
    Fujino
    M
    ,  
    Yamazaki
    K
    ,  
    Onodera
    Y
    ,  
    Taguchi
    H
    ,  
    Katoh
    N
    .  et al. 
    Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
    Int J Radiat Oncol Biol Phys
    2008
    70
    374
    81
     PubMed
  91. Svedman
    C
    ,  
    Karlsson
    K
    ,  
    Rutkowska
    E
    ,  
    Sandström
    P
    ,  
    Blomgren
    H
    ,  
    Lax
    I
    .  et al. 
    Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney.
    Acta Oncol
    2008
    47
    1578
    83
     PubMed
  92. Joyner
    M
    ,  
    Salter
    BJ
    ,  
    Papanikolaou
    N
    ,  
    Fuss
    M
    .  
    Stereotactic body radiation therapy for centrally located lung lesions.
    Acta Oncol
    2006
    45
    802
    7
     PubMed
  93. Hamamoto
    Y
    ,  
    Kataoka
    M
    ,  
    Yamashita
    M
    ,  
    Shinkai
    T
    ,  
    Kubo
    Y
    ,  
    Sugawara
    Y
    .  et al. 
    Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer.
    Jpn J Clin Oncol
    2010
    40
    125
    9
     PubMed
  94. Bradley
    JD
    ,  
    El
    Naqa
    I
    ,  
    Drzymala
    RE
    ,  
    Trovo
    M
    ,  
    Jones
    G
    ,  
    Denning
    MD
    .  
    Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Int J Radiat Oncol Biol Phys
    2010
    77
    1146
    50
     PubMed
  95. Unger
    K
    ,  
    Ju
    A
    ,  
    Oermann
    E
    ,  
    Suy
    S
    ,  
    Yu
    X
    ,  
    Vahdat
    S
    .  et al. 
    CyberKnife for hilar lung tumors: report of clinical response and toxicity.
    J Hematol Oncol
    2010
    3
    39
     PubMed
  96. Trovo
    M
    ,  
    Linda
    A
    ,  
    El
    Naqa
    I
    ,  
    Javidan-Nejad
    C
    ,  
    Bradley
    J
    .  
    Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT).
    Lung Cancer
    2010
    69
    77
    85
     PubMed
  97. Stintzing
    S
    ,  
    Hoffmann
    RT
    ,  
    Heinemann
    V
    ,  
    Kufeld
    M
    ,  
    Muacevic
    A
    .  
    Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients.
    Eur J Cancer
    2010
    46
    1026
    32
     PubMed
  98. Goodman
    KA
    ,  
    Wiegner
    EA
    ,  
    Maturen
    KE
    ,  
    Zhang
    Z
    ,  
    Mo
    Q
    ,  
    Yang
    G
    .  et al. 
    Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
    Int J Radiat Oncol Biol Phys
    2010
    78
    486
    93
     PubMed
  99. Stintzing
    S
    ,  
    Hoffmann
    RT
    ,  
    Heinemann
    V
    ,  
    Kufeld
    M
    ,  
    Rentsch
    M
    ,  
    Muacevic
    A
    .  
    Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors.
    Ann Surg Oncol
    2010
    17
    2877
    83
     PubMed
  100. Jorcano
    S
    ,  
    Molla
    M
    ,  
    Escude
    L
    ,  
    Sanz
    S
    ,  
    Hidalgo
    A
    ,  
    Toscas
    JI
    .  et al. 
    Hypofractionated extracranial stereotactic radiotherapy boost for gynecologic tumors: a promising alternative to high-dose rate brachytherapy.
    Technol Cancer Res Treat
    2010
    9
    509
    14
     PubMed
  101. Guckenberger
    M
    ,  
    Bachmann
    J
    ,  
    Wulf
    J
    ,  
    Mueller
    G
    ,  
    Krieger
    T
    ,  
    Baier
    K
    .  et al. 
    Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer.
    Radiother Oncol
    2010
    94
    53
    9
     PubMed
  102. Milano
    MT
    ,  
    Philip
    A
    ,  
    Okunieff
    P
    .  
    Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses.
    Int J Radiat Oncol Biol Phys
    2009
    73
    832
    7
     PubMed
  103. Koto
    M
    ,  
    Takai
    Y
    ,  
    Ogawa
    Y
    ,  
    Matsushita
    H
    ,  
    Takeda
    K
    ,  
    Takahashi
    C
    .  et al. 
    A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer.
    Radiother Oncol
    2007
    85
    429
    34
     PubMed
  104. Grills
    IS
    ,  
    Mangona
    VS
    ,  
    Welsh
    R
    ,  
    Chmielewski
    G
    ,  
    McInerney
    E
    ,  
    Martin
    S
    .  et al. 
    Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
    J Clin Oncol
    2010
    28
    928
    35
     PubMed
  105. Seo
    YS
    ,  
    Kim
    MS
    ,  
    Yoo
    SY
    ,  
    Cho
    CK
    ,  
    Choi
    CW
    ,  
    Kim
    JH
    .  et al. 
    Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma.
    J Surg Oncol
    2010
    102
    209
    14
     PubMed
  106. Townsend
    NC
    ,  
    Huth
    BJ
    ,  
    Ding
    W
    ,  
    Garber
    B
    ,  
    Mooreville
    M
    ,  
    Arrigo
    S
    .  et al. 
    Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer.
    Am J Clin Oncol
    2011
    34
    6
    10
     PubMed
  107. Son
    SH
    ,  
    Choi
    BO
    ,  
    Ryu
    MR
    ,  
    Kang
    YN
    ,  
    Jang
    JS
    ,  
    Bae
    SH
    .  et al. 
    Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication.
    Int J Radiat Oncol Biol Phys
    2010
    78
    1073
    80
     PubMed
  108. Moll
    M
    ,  
    Escude
    L
    ,  
    Nouet
    P
    ,  
    Popowski
    Y
    ,  
    Hidalgo
    A
    ,  
    Rouzaud
    M
    .  et al. 
    Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy?
    Int J Radiat Oncol Biol Phys
    2005
    62
    118
    24
     PubMed
  109. King
    CR
    ,  
    Brooks
    JD
    ,  
    Gill
    H
    ,  
    Pawlicki
    T
    ,  
    Cotrutz
    C
    ,  
    Presti
    JC
    Jr
    .  
    Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    Int J Radiat Oncol Biol Phys
    2009
    73
    1043
    8
     PubMed
  110. Yamashita
    H
    ,  
    Kobayashi-Shibata
    S
    ,  
    Terahara
    A
    ,  
    Okuma
    K
    ,  
    Haga
    A
    ,  
    Wakui
    R
    .  et al. 
    Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.
    Radiat Oncol
    2010
    5
    32
     PubMed
  111. Takeda
    A
    ,  
    Ohashi
    T
    ,  
    Kunieda
    E
    ,  
    Enomoto
    T
    ,  
    Sanuki
    N
    ,  
    Takeda
    T
    .  et al. 
    Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Int J Radiat Oncol Biol Phys
    2010
    77
    685
    90
     PubMed
  112. Bolzicco
    G
    ,  
    Favretto
    MS
    ,  
    Scremin
    E
    ,  
    Tambone
    C
    ,  
    Tasca
    A
    ,  
    Guglielmi
    R
    .  
    Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.
    Technol Cancer Res Treat
    2010
    9
    473
    7
     PubMed
  113. Oermann
    EK
    ,  
    Slack
    RS
    ,  
    Hanscom
    HN
    ,  
    Lei
    S
    ,  
    Suy
    S
    ,  
    Park
    HU
    .  et al. 
    A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Technol Cancer Res Treat
    2010
    9
    453
    62
     PubMed
  114. Aluwini
    S
    ,  
    van Rooij
    P
    ,  
    Hoogeman
    M
    ,  
    Bangma
    C
    ,  
    Kirkels
    WJ
    ,  
    Incrocci
    L
    .  et al. 
    CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance.
    J Endourol
    2010
    24
    865
    9
     PubMed
  115. Freeman
    DE
    ,  
    King
    CR
    .  
    Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.
    Radiat Oncol
    2011
    6
    3
     PubMed
  116. Meyer
    JL
    ,  
    Verhey
    L
    ,  
    Xia
    P
    ,  
    Wong
    J
    .  
    New technologies in the radiotherapy clinic.
    Front Radiat Ther Oncol
    2007
    40
    1
    17
     PubMed
  117. MEDCAC Meeting: Radiation Therapy for Localized Prostate Cancer. Baltimore, MD: Centers for Medicare & Medicaid Services; 21 April 2010. Accessed atwww.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?&bc=BAAAAAAAAAAA&MEDCACId=54&on 15 March 2011.
  118. Nguyen
    NP
    ,  
    Garland
    L
    ,  
    Welsh
    J
    ,  
    Hamilton
    R
    ,  
    Cohen
    D
    ,  
    Vinh-Hung
    V
    .  
    Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.
    Cancer Treat Rev
    2008
    34
    719
    27
     PubMed
  119. Brock
    J
    ,  
    Ashley
    S
    ,  
    Bedford
    J
    ,  
    Nioutsikou
    E
    ,  
    Partridge
    M
    ,  
    Brada
    M
    .  
    Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer.
    Clin Oncol (R Coll Radiol)
    2008
    20
    666
    76
     PubMed
  120. Chi
    A
    ,  
    Liao
    Z
    ,  
    Nguyen
    NP
    ,  
    Xu
    J
    ,  
    Stea
    B
    ,  
    Komaki
    R
    .  
    Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.
    Radiother Oncol
    2010
    94
    1
    11
     PubMed
  121. Calcerrada Díaz-Santos
    N
    ,  
    BlascoAmaro
    JA
    ,  
    Cardiel
    GA
    ,  
    Andradas Aragonés
    E
    .  
    The safety and efficacy of robotic image-guided radiosurgery system treatment for intra- and extracranial lesions: a systematic review of the literature.
    Radiother Oncol
    2008
    89
    245
    53
     PubMed
  122. Khrizman
    P
    ,  
    Small
    W
    Jr
    ,  
    Dawson
    L
    ,  
    Benson
    AB
    3rd
    .  
    The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings.
    Clin Colorectal Cancer
    2010
    9
    136
    43
     PubMed
  123. Sawrie
    SM
    ,  
    Fiveash
    JB
    ,  
    Caudell
    JJ
    .  
    Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity.
    Cancer Control
    2010
    17
    111
    9
     PubMed
  124. Siva
    S
    ,  
    MacManus
    M
    ,  
    Ball
    D
    .  
    Stereotactic radiotherapy for pulmonary oligometastases: a systematic review.
    J Thorac Oncol
    2010
    5
    1091
    9
     PubMed
  125. Benedict
    SH
    ,  
    Yenice
    KM
    ,  
    Followill
    D
    ,  
    Galvin
    JM
    ,  
    Hinson
    W
    ,  
    Kavanagh
    B
    .  et al. 
    Stereotactic body radiation therapy: the report of AAPM Task Group 101.
    Med Phys
    2010
    37
    4078
    101
     PubMed
  126. Chang
    BK
    ,  
    Timmerman
    RD
    .  
    Stereotactic body radiation therapy: a comprehensive review.
    Am J Clin Oncol
    2007
    30
    637
    44
     PubMed
  127. Olsen
    CC
    ,  
    Welsh
    J
    ,  
    Kavanagh
    BD
    ,  
    Franklin
    W
    ,  
    McCarter
    M
    ,  
    Cardenes
    HR
    .  et al. 
    Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy.
    Int J Radiat Oncol Biol Phys
    2009
    73
    1414
    24
     PubMed
  128. Seong
    J
    ,  
    Lee
    IJ
    ,  
    Shim
    SJ
    ,  
    Lim do
    H
    ,  
    Kim
    TH
    ,  
    Kim
    JH
    .  et al. 
    A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea.
    Liver Int
    2009
    29
    147
    52
     PubMed
  129. Beitler
    JJ
    ,  
    Makara
    D
    ,  
    Silverman
    P
    ,  
    Lederman
    G
    .  
    Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma.
    Am J Clin Oncol
    2004
    27
    646
    8
     PubMed
  130. Henderson
    M
    ,  
    McGarry
    R
    ,  
    Yiannoutsos
    C
    ,  
    Fakiris
    A
    ,  
    Hoopes
    D
    ,  
    Williams
    M
    .  et al. 
    Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys
    2008
    72
    404
    9
     PubMed
  131. Kawase
    T
    ,  
    Takeda
    A
    ,  
    Kunieda
    E
    ,  
    Kokubo
    M
    ,  
    Kamikubo
    Y
    ,  
    Ishibashi
    R
    .  et al. 
    Extrapulmonary soft-tissue fibrosis resulting from hypofractionated stereotactic body radiotherapy for pulmonary nodular lesions.
    Int J Radiat Oncol Biol Phys
    2009
    74
    349
    54
     PubMed
  132. Ricardi
    U
    ,  
    Filippi
    AR
    ,  
    Guarneri
    A
    ,  
    Giglioli
    FR
    ,  
    Mantovani
    C
    ,  
    Fiandra
    C
    .  et al. 
    Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Acta Oncol
    2009
    48
    571
    7
     PubMed
  133. Rusthoven
    KE
    ,  
    Hammerman
    SF
    ,  
    Kavanagh
    BD
    ,  
    Birtwhistle
    MJ
    ,  
    Stares
    M
    ,  
    Camidge
    DR
    .  
    Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
    Acta Oncol
    2009
    48
    578
    83
     PubMed
  134. Hoopes
    DJ
    ,  
    Tann
    M
    ,  
    Fletcher
    JW
    ,  
    Forquer
    JA
    ,  
    Lin
    PF
    ,  
    Lo
    SS
    .  et al. 
    FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Lung Cancer
    2007
    56
    229
    34
     PubMed
  135. Muacevic
    A
    ,  
    Drexler
    C
    ,  
    Wowra
    B
    ,  
    Schweikard
    A
    ,  
    Schlaefer
    A
    ,  
    Hoffmann
    RT
    .  et al. 
    Technical description, phantom accuracy, and clinical feasibility for single-session lung radiosurgery using robotic image-guided real-time respiratory tumor tracking.
    Technol Cancer Res Treat
    2007
    6
    321
    8
     PubMed
  136. Paludan
    M
    ,  
    Traberg Hansen
    A
    ,  
    Petersen
    J
    ,  
    Grau
    C
    ,  
    Høyer
    M
    .  
    Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: is there a dose-volume dependency?.
    Acta Oncol
    2006
    45
    818
    22
     PubMed
  137. Scorsetti
    M
    ,  
    Navarria
    P
    ,  
    Facoetti
    A
    ,  
    Lattuada
    P
    ,  
    Urso
    G
    ,  
    Mirandola
    A
    .  et al. 
    Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer.
    Anticancer Res
    2007
    27
    3615
    9
     PubMed
  138. Hof
    H
    ,  
    Zgoda
    J
    ,  
    Nill
    S
    ,  
    Hoess
    A
    ,  
    Kopp-Schneider
    A
    ,  
    Herfarth
    K
    .  et al. 
    Time- and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy.
    Int J Radiat Oncol Biol Phys
    2010
    77
    1369
    74
     PubMed
  139. Gerszten
    PC
    ,  
    Ozhasoglu
    C
    ,  
    Burton
    SA
    ,  
    Welch
    WC
    ,  
    Vogel
    WJ
    ,  
    Atkins
    BA
    .  et al. 
    CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum.
    Neurosurg Focus
    2003
    15
    7
     PubMed
  140. Fuller
    DB
    ,  
    Naitoh
    J
    ,  
    Lee
    C
    ,  
    Hardy
    S
    ,  
    Jin
    H
    .  
    Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Int J Radiat Oncol Biol Phys
    2008
    70
    1588
    97
     PubMed
  141. Madsen
    BL
    ,  
    Hsi
    RA
    ,  
    Pham
    HT
    ,  
    Fowler
    JF
    ,  
    Esagui
    L
    ,  
    Corman
    J
    .  
    Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Int J Radiat Oncol Biol Phys
    2007
    67
    1099
    105
     PubMed
Figure.
A linear accelerator–based stereotactic radiosurgery and stereotactic body radiation therapy system.

The system incorporates a high-definition, 120-leaf multileaf collimator; robotic couch; cone-beam computed tomography; and stereoradiograph target–verification system. (Photo courtesy of Varian Medical Systems, Palo Alto, California. All rights reserved.)

Appendix Figure.
Summary of evidence search and selection.

Appendix Table 1.

Electronic Database Searches

Appendix Table 1.

Appendix Table 2.

Search Strings

Appendix Table 2.

Appendix Table 3.

Summary of SBRT Studies, by Cancer Type

Appendix Table 3.

Appendix Table 4.

Comparative Clinical Trials Involving SBRT

Appendix Table 4.

Appendix Table 5.

Systematic Reviews

Appendix Table 5.
PDF Supplemental Content
PDF Supplemental Content
PDF Supplemental Content

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Tipton K, Launders JH, Inamdar R, et al. Stereotactic Body Radiation Therapy: Scope of the Literature. Ann Intern Med. 2011;154:737–745. doi: https://doi.org/10.7326/0003-4819-154-11-201106070-00343

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2011;154(11):737-745.

DOI: 10.7326/0003-4819-154-11-201106070-00343

26 Citations

Related Articles

Treatment of Thymoma-Associated Myasthenia Gravis With Stereotactic Body Radiotherapy: A Case Report
Annals of Internal Medicine; 165 (4): 300-301
A Rigorous Mind Meets Her Yielding Body: Intellectual Life and Meaning-Making in Wit
Annals of Internal Medicine; 147 (5): 353-356
Narrative Review: Screening for Colorectal Cancer in Patients with a First-Degree Relative with Colonic Neoplasia
Annals of Internal Medicine; 143 (3): 190-198
Description of a Hepatitis C Outbreak in a Cancer Clinic
Annals of Internal Medicine; 142 (11): I-38
View MoreView Less

Journal Club

In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
Annals of Internal Medicine; 170 (12): JC67
In patients with cancer who were starting chemotherapy, apixaban reduced VTE and increased major bleeding at 180 d
Annals of Internal Medicine; 170 (6): JC29
In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
Review: In patients with a first VTE, extended testing for undiagnosed cancer does not reduce mortality
Annals of Internal Medicine; 167 (12): JC64
View MoreView Less

Related Point of Care

Prostate Cancer
Annals of Internal Medicine; 163 (11): ITC1
Care of the Adult Cancer Survivor
Annals of Internal Medicine; 158 (11): ITC6-1
View MoreView Less

Related Topics

Hematology/Oncology

Hematology/Oncology.

PubMed Articles

Loss of p57KIP2 expression confers resistance to contact inhibition in human androgenetic trophoblast stem cells.
Proc Natl Acad Sci U S A 2019.
CD138-negative plasma cell myeloma: a diagnostic challenge and a unique entity.
BMJ Case Rep 2019;12(11):.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×